Grace Wong (immunologist)
 | This medical article is a stub. You can help EverybodyWiki by expanding it. |
 | This oncology article is a stub. You can help EverybodyWiki by expanding it. |
Grace Wong, PhD, is the founder and Chief Executive Officer (for Asia & USA), of ActoKine Therapeutic[1] of Chestnut Hill (Newton), Massachusetts. The company, ActoKine Therapeutics, is involved in cytokine research in several therapeutic areas, including oncology. They collaborate with international drug companies and institutions towards the goal of solving cancer therapy problems related to toxic and other negative side effects of the oncotherapies on normal cells.
Dr. Wong's recent work has involved drug repurposing[2], which she describes as ‘drug rescue’ and ‘drug indication switch’.[3] A significant advantage of drug repositioning over traditional drug development is that, since the repositioned drug has already passed a significant number of toxicity and other tests, its safety is known and the risk of failure for reasons of adverse toxicology are reduced. More than 90% of drugs fail during development,[4] Testing is typically concerned with safety and efficacy, so it's efficacy remains to be tested when it's relative safet has been determined beforehand (reducing costs and animals and humans used).
See Also[edit]
- Cancer therapy
- Cytogenetics
- Cytokines
- Cancer immunotherapy#Cytokine therapy
- Drug development
- Drug repositioning
References[edit]
- ↑ Company website for ActoKine Therapeutics of Chestnut Hill
- ↑ Drug repositioning is known also as Drug repurposing, Drug re-profiling, Therapeutic Switching, and Drug re-tasking.
- ↑ Home page for the quarterly pharmaceutical Journal Drug Repurposing, Rescue, and Repositioning, published by Mary Ann Liebert, Inc. publishers, ISSN: 2332-025, Online ISSN: 2332-0265
- ↑ DiMasa JA, Hansen RW, Grabowski HG, Lasagna L 1991. Cost of Innovation in the Pharmaceutical Industry. J Health Economics 10, 107.
Further reading[edit]
- Chong CR, Sullivan DJ (August 2007). "New uses for old drugs". Nature. 448 (7154): 645–6. doi:10.1038/448645a. PMID 17687303.
- Tartaglia LA (November 2006). "Complementary new approaches enable repositioning of failed drug candidates". Expert Opinion on Investigational Drugs. 15 (11): 1295–8. doi:10.1517/13543784.15.11.1295. PMID 17040191.
- Aronson JK (November 2007). "Old drugs – new uses". British Journal of Clinical Pharmacology. 64 (5): 563–5. doi:10.1111/j.1365-2125.2007.03058.x. PMC 2203255. PMID 17935601.
- Hughes B (February 2008). "2007 FDA drug approvals: a year of flux". Nature reviews. Drug discovery. 7 (2): 107–9. doi:10.1038/nrd2514. PMID 18246607.
External links[edit]
This article "Grace Wong (immunologist)" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
